Over the past three months, three pharmaceutical companies voluntarily withdrew three cancer indications for drugs that had previously received accelerated approvals from FDA, but ultimately failed to meet agreed-upon endpoints in confirmatory trials required for regular approvals.
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
